CDK4 and neoplasm: Importantly, tumor cells have numerous mechanisms of resistance to CDK4/6 inhibitors at their disposal, which are both cell cycle specific (e.g., CCNE amplification and CDK2 hyperactivation) and independent of the cell cycle (e.g., activation of PI3K/AKT/mTOR signaling) (reviewed in [198]).